Loading
A phase 3 trial of Durvalumab, Tremelimumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC is a phase 3 interventional study registered as NCT05557838 by AstraZeneca, with 214 participants enrolled, started 2023-02-15 and due to reach its primary completion in 2026-09-30. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/